Purple Biotech Ltd Cash Flow Conversion Efficiency
Purple Biotech Ltd cash flow conversion efficiency. Based on the latest financial reports, Purple Biotech Ltd (PPBT) has a cash flow conversion efficiency ratio of -0.033x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-1.07 Million ≈ $-2.86K USD) by net assets (ILA32.81 Million ≈ $87.98K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Purple Biotech Ltd (2017–2024)
Cash flow conversion efficiency of Purple Biotech Ltd from 2017 to 2024. This chart illustrates how Purple Biotech Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Purple Biotech Ltd for real-time trading data and today's change.
Purple Biotech Ltd Cash Flow Conversion Ratio Explained
Purple Biotech Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Purple Biotech Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Purple Biotech Ltd ranked by their cash flow conversion efficiency. Also see how much is Purple Biotech Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PVW Resources Ltd
AU:PVW
|
-1.696x |
|
Sumber Mas Konstruksi Tbk PT
JK:SMKM
|
-0.018x |
|
Aqua Metals Inc
NASDAQ:AQMS
|
-0.276x |
|
GLOBAL UAV TECHS
F:YAB
|
0.036x |
|
AquaBounty Technologies Inc
NASDAQ:AQB
|
0.480x |
|
Whitebark Energy Ltd
AU:WBE
|
0.308x |
|
D.T.C. Industries Public Company Limited
BK:DTCI
|
-0.015x |
|
Destiny Media Technologies Inc
V:DSY
|
0.158x |
Annual Cash Flow Conversion Efficiency for Purple Biotech Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Purple Biotech Ltd from 2017 to 2024. Review PPBT FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA32.91 Million ≈ $88.23K |
ILA-14.37 Million ≈ $-38.52K |
-0.437x | +24.86% |
| 2023-12-31 | ILA34.30 Million ≈ $91.95K |
ILA-19.93 Million ≈ $-53.42K |
-0.581x | -63.50% |
| 2022-12-31 | ILA47.10 Million ≈ $126.27K |
ILA-16.73 Million ≈ $-44.87K |
-0.355x | -51.69% |
| 2021-12-31 | ILA65.11 Million ≈ $174.55K |
ILA-15.25 Million ≈ $-40.89K |
-0.234x | -54.50% |
| 2020-12-31 | ILA79.75 Million ≈ $213.81K |
ILA-12.09 Million ≈ $-32.42K |
-0.152x | +70.50% |
| 2019-12-31 | ILA10.86 Million ≈ $29.11K |
ILA-5.58 Million ≈ $-14.96K |
-0.514x | +33.31% |
| 2018-12-31 | ILA11.00 Million ≈ $29.50K |
ILA-8.48 Million ≈ $-22.73K |
-0.771x | +23.24% |
| 2017-12-31 | ILA8.59 Million ≈ $23.04K |
ILA-8.63 Million ≈ $-23.13K |
-1.004x | -- |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, whi… Read more